Natasha Dave1, Jiao Wu1, Sandhya Thomas2,3. 1. Section of Nephrology, Department of Medicine, Baylor College of Medicine, Selzman Institute for Kidney Health, Houston, TX, 77030, USA. 2. Section of Nephrology, Department of Medicine, Baylor College of Medicine, Selzman Institute for Kidney Health, Houston, TX, 77030, USA. ssthomas@bcm.edu. 3. Michael E. Debakey Veterans Affairs Medical Center, Houston, TX, 77030, USA. ssthomas@bcm.edu.
Abstract
PURPOSE OF REVIEW: Insulin resistance is an early complication of chronic kidney disease (CKD) associated with worsening cardiovascular outcomes. This review will evaluate mechanisms responsible for CKD-induced insulin resistance and therapies currently available. RECENT FINDINGS: Recent mechanisms have been identified including SIRPα and specific E3 ubiquitin ligases causing insulin resistance in CKD. The hallmark finding in these mechanisms is degradation of the insulin receptor substrate 1 (IRS1) which impairs intracellular insulin signaling and ultimately metabolism. The mechanisms responsible for insulin resistance in CKD include inflammation, oxidative stress, elevations in aldosterone, angiotensin II, uremic toxins, and metabolic acidosis. Potential treatments currently available for CKD-induced insulin resistance include lifestyle modification and metformin. Potential future treatments may include glucagon-like peptide agonists, SGLT2 inhibitors, and thiazolidinediones. Investigations into molecular mechanisms responsible for insulin resistance in CKD may provide new therapeutic targets while current therapies may prevent the catabolic sequelae of CKD and ameliorate its cardiovascular consequences.
PURPOSE OF REVIEW: Insulin resistance is an early complication of chronic kidney disease (CKD) associated with worsening cardiovascular outcomes. This review will evaluate mechanisms responsible for CKD-induced insulin resistance and therapies currently available. RECENT FINDINGS: Recent mechanisms have been identified including SIRPα and specific E3 ubiquitin ligases causing insulin resistance in CKD. The hallmark finding in these mechanisms is degradation of the insulin receptor substrate 1 (IRS1) which impairs intracellular insulin signaling and ultimately metabolism. The mechanisms responsible for insulin resistance in CKD include inflammation, oxidative stress, elevations in aldosterone, angiotensin II, uremic toxins, and metabolic acidosis. Potential treatments currently available for CKD-induced insulin resistance include lifestyle modification and metformin. Potential future treatments may include glucagon-like peptide agonists, SGLT2 inhibitors, and thiazolidinediones. Investigations into molecular mechanisms responsible for insulin resistance in CKD may provide new therapeutic targets while current therapies may prevent the catabolic sequelae of CKD and ameliorate its cardiovascular consequences.
Authors: Mark O Goodarzi; Jinrui Cui; Yii-Der I Chen; Willa A Hsueh; Xiuqing Guo; Jerome I Rotter Journal: Am J Physiol Endocrinol Metab Date: 2011-05-31 Impact factor: 4.310
Authors: Juan C Molero; Thomas E Jensen; Phil C Withers; Michelle Couzens; Herbert Herzog; Christine B F Thien; Wallace Y Langdon; Ken Walder; Maria A Murphy; David D L Bowtell; David E James; Gregory J Cooney Journal: J Clin Invest Date: 2004-11 Impact factor: 14.808
Authors: Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder Journal: N Engl J Med Date: 2016-02-17 Impact factor: 91.245
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Christianne L Roumie; Adriana M Hung; Gregory B Russell; Jan Basile; Kathryn Evans Kreider; John Nord; Thomas M Ramsey; Anjay Rastogi; Mary Ellen Sweeney; Leonardo Tamariz; William J Kostis; Jonathan S Williams; Athena Zias; William C Cushman Journal: Hypertension Date: 2019-12-23 Impact factor: 10.190